Tag: Clarity Pharmaceuticals
Clarity secures large-scale manufacturing agreement for copper-64
Clarity Pharmaceuticals, an Australia-based clinical-stage radiopharmaceutical company, has announced a manufacturing supply agreement aimed at scaling up copper-64 production, as the company advances its radiopharmaceutical development program toward potential commercialisation.
Clarity and Nucleus RadioPharma scale up manufacturing for cancer treatment
Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company, has entered into a Master Services Agreement (MSA) and Clinical Manufacturing Agreement for the production of 67Cu-SAR-bisPSMA, a radiopharmaceutical treatment for prostate cancer.
Clarity Pharmaceuticals inks clinical supply agreement for prostate cancer imaging products
ASX-listed Clarity Pharmaceuticals has signed a Master Service Agreement and a Clinical Supply Agreement with Siemens Healthineers company PETNET Solutions Inc for the supply expansion of Clarity’s 64Cu SAR-bisPSMA, a diagnostic radiopharmaceutical product for prostate cancer imaging.
Featured Article
Australian Manufacturing Week 2026 enters final run-up to Brisbane debut
Australia’s manufacturing sector continues to play a critical role in the national economy, underpinned by ongoing investment in advanced technologies, automation, and high-value production.
